

Anti-DLL4 hlgG2 Antibody(demcizumab)

Product information


GM-88253AB-10	10 µg
GM-88253AB-100	100 µg
GM-88253AB-1000	1 mg

Antibody Information

Species Reactivity	Human
Clone	demcizumab
Source/Isotype	Human IgG2 (S377A,delta447K), Kappa
Application	/
Specificity	Detects DLL4
Gene	DLL4
Other Names	Delta4
Gene ID	54567 (Human)
Background	Demcizumab (dancizumab, OMP-21M18) is a humanized monoclonal antibody (IGG2) developed by OncoMed Pharmaceuticals, targeting DLL4(Delta-like ligand 4) , which belongs to the Notch signaling pathway inhibitor. The core mechanism is the inhibition of the Notch pathway by blocking the binding of DLL4 to NOTCH1/4 receptors, and the inhibition of the Notch signaling pathway by the DLL4-like ligand, induction of tumorigenic “Non-functional angiogenesis”(vascular endothelial hyperproliferation but lack of intact lumen and blood flow perfusion, aggravating tumor hypoxia) and reduction of tumor stem cell (CSCs) frequency, while potentially modulating the immune microenvironment.
Storage	Store at 2-8°C short term (1-2 weeks).Store at ≤ -20°C long term. Avoid repeated freeze-thaw.
Formulation	Supplied as a 0.2 µm filtered solution of PBS, pH7.2-7.4.
Endotoxin	< 1 EU/mg, determined by LAL gel clotting assay


Version:3.1

SDS-PAGE



On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-HPLC



The purity of this product is more than 95% verified by SEC-HPLC.